Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments. Conducted entirely at the University of Colorado Anschutz , this research has advanced from the laboratory to a Phase 1 clinical trial on the campus.
The findings, published today in Cancer Research Communications , outline a promising strategy that combines a PARP inhibitor, a targeted drug used to treat certain types of ovarian cancer, with a novel therapy, SM08502, to attack cancer from two directions. This innovative approach boosts the effectiveness of the treatment, even for patients who are no longer responding to PARP inhibitor therapy.
“This achievement exemplifies true bench-to-bedside innovation entirely done at CU Anschutz,” said the paper’s first author Bradley Corr, MD, associate professor and director of clinical research in gynecologic oncology at CU Anschutz. “To the best of our knowledge, this is the first clinical trial to successfully combine these classes of drugs. While the concept has been discussed before, no one has moved it into the clinic until now. That’s what makes this approach truly novel.”
Ovarian cancer, particularly high-grade serous ovarian cancer, is notoriously difficult to treat. PARP inhibitors, used as a treatment for ovarian cancer for more than a decade, have transformed care for patients with a BRCA genetic mutation or homologous recombination deficiency (HRD), significantly extending survival rates. However, many ovarian cancer patients eventually develop resistance to PARP inhibitors, leaving few treatment alternatives.
The CU Cancer Center experts discovered that when cancer cells become resistant to PARP inhibitors, they switch on a “backup survival system” called WNT signaling. This helps the cancer keep growing in certain patients, even when PARP drugs should stop it.
Because of this outcome, they decided to test a new therapy called SM08502 (Cirtuvivint). They found that instead of directly blocking WNT signaling (which can cause bad side effects), this drug changes how certain cancer genes are processed (spliced), which indirectly shuts down WNT signaling. This resulted in impressive findings:
“I began my career focused on understanding why ovarian cancer becomes resistant to therapy. PARP inhibitors have been a cornerstone of my research, but resistance remains a major challenge. Early on, we characterized therapy-resistant cell lines, and this research represents the next step - developing strategies to help patients who may have no other options,” said senior author Benjamin Bitler, PhD, associate professor and the D. Thomas and Kay L. Dunton Endowed Chair in Ovarian Cancer Research at CU Anschutz.
Bitler credits CU Anschutz’s collaborative ecosystem - and the partnership with clinicians like Corr - for turning this milestone into reality.
The authors mention this approach has the potential to reach beyond ovarian cancer to other tumors with similar resistance mechanisms. Both drugs are oral, making treatment more accessible, and the combination may even help reduce risks associated with long-term PARP inhibitor use.
To explore enrollment in this clinical trial, visit www.clinicaltrials.gov/study/NCT06856499 .
For information on ovarian cancer trials at CU Cancer Center, visit the center’s clinical trial website .
About the University of Colorado Anschutz
The University of Colorado Anschutz is a world-class academic medical campus at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado – which see more than two million adult and pediatric patient visits yearly. Innovative, interconnected and highly collaborative, CU Anschutz delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by $910 million in annual research funding, including $757 million in sponsored awards and $153 million in philanthropic gifts.
The findings, published today in Cancer Research Communications , outline a promising strategy that combines a PARP inhibitor, a targeted drug used to treat certain types of ovarian cancer, with a novel therapy, SM08502, to attack cancer from two directions. This innovative approach boosts the effectiveness of the treatment, even for patients who are no longer responding to PARP inhibitor therapy.
Cancer Research Communications
SM08502-mediated β-catenin repression synergizes with olaparib to inhibit tumor progression
4-Dec-2025